United Therapeutics Corporation (UTHR)
Largest Insider Buys in Sector
UTHR Stock Price History Chart
UTHR Stock Performance
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension …
Insider Activity of United Therapeutics Corporation
Over the last 12 months, insiders at United Therapeutics Corporation have bought $0 and sold $319.58M worth of United Therapeutics Corporation stock.
On average, over the past 5 years, insiders at United Therapeutics Corporation have bought $0 and sold $152.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4 shares for transaction amount of $331 was made by PATUSKY CHRISTOPHER (director) on 2019‑06‑10.
List of Insider Buy and Sell Transactions, United Therapeutics Corporation
| 2024-12-18 | Sale | director | 26,209 0.0614% | $373.22 | $9.78M | -3.75% | ||
| 2024-12-16 | Sale | PRESIDENT AND COO | 10,000 0.0223% | $370.14 | $3.7M | -2.46% | ||
| 2024-12-09 | Sale | PRESIDENT AND COO | 10,000 0.0224% | $367.69 | $3.68M | -1.31% | ||
| 2024-12-05 | Sale | EVP & GENERAL COUNSEL | 7,700 0.0173% | $374.37 | $2.88M | -3.05% | ||
| 2024-12-02 | Sale | PRESIDENT AND COO | 10,000 0.0224% | $370.51 | $3.71M | -0.84% | ||
| 2024-11-25 | Sale | PRESIDENT AND COO | 10,000 0.0225% | $372.75 | $3.73M | +0.27% | ||
| 2024-11-21 | Sale | EVP & GENERAL COUNSEL | 7,700 0.0173% | $367.36 | $2.83M | +0.63% | ||
| 2024-11-18 | Sale | PRESIDENT AND COO | 10,000 0.0224% | $359.21 | $3.59M | +1.21% | ||
| 2024-11-11 | Sale | director | 1,750 0.004% | $412.48 | $721,840 | -7.79% | ||
| 2024-11-11 | Sale | PRESIDENT AND COO | 15,000 0.034% | $407.32 | $6.11M | -7.79% | ||
| 2024-11-08 | Sale | director | 224 0.0005% | $412.28 | $92,350 | -9.84% | ||
| 2024-11-07 | Sale | PRESIDENT AND COO | 15,000 0.0334% | $401.44 | $6.02M | -8.12% | ||
| 2024-11-06 | Sale | PRESIDENT AND COO | 10,000 0.0222% | $394.96 | $3.95M | -6.89% | ||
| 2024-11-05 | Sale | director | 10,000 0.0228% | $381.70 | $3.82M | 0.00% | ||
| 2024-11-04 | Sale | CFO AND TREASURER | 4,511 0.0101% | $374.02 | $1.69M | -1.72% | ||
| 2024-11-01 | Sale | director | 510 0.0012% | $376.63 | $192,080 | -0.94% | ||
| 2024-11-01 | Sale | PRESIDENT AND COO | 14,700 0.033% | $374.46 | $5.5M | -0.94% | ||
| 2024-10-28 | Sale | CFO AND TREASURER | 4,533 0.0096% | $350.00 | $1.59M | +0.80% | ||
| 2024-10-21 | Sale | CFO AND TREASURER | 4,515 0.01% | $366.99 | $1.66M | -0.03% | ||
| 2024-10-14 | Sale | CFO AND TREASURER | 4,525 0.0101% | $355.88 | $1.61M | +3.70% |
Insider Historical Profitability
| PATUSKY CHRISTOPHER | director | 900 0.002% | $360.87 | 5 | 68 | <0.0001% |
| ROTHBLATT MARTINE A | Chairperson & CEO | 130 0.0003% | $360.87 | 30 | 1099 | +20.16% |
Institutional Investor Ownership
| BlackRock | $1.28B | 12.55 | 5.57M | +5.15% | +$62.61M | 0.03 | |
| The Vanguard Group | $1.08B | 10.56 | 4.68M | +0.2% | +$2.16M | 0.02 | |
| Wellington Management Company | $783.86M | 7.69 | 3.41M | -10.06% | -$87.7M | 0.13 | |
| Avoro Capital Advisors Llc | $656.74M | 6.45 | 2.86M | 0% | +$0 | 7.87 | |
| Renaissance Technologies | $494.29M | 4.85 | 2.15M | -0.85% | -$4.25M | 0.79 |